Yulia Deng

Yulia Deng

Genentech, Inc - South San Francisco / United States
Others
AD Scientific Index ID: 4380812
-
person_outline Yulia Deng's MOST POPULAR ARTICLES
1-) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLCMA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...New England Journal of Medicine 378 (24), 2288-2301, 201825292018
2-) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialE Felip, N Altorki, C Zhou, T Csőszi, I Vynnychenko, O Goloborodko, ...The Lancet 398 (10308), 1344-1357, 20218512021
3-) Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in …M Reck, TSK Mok, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, ...The Lancet Respiratory Medicine 7 (5), 387-401, 20198332019
4-) OA05. 07 IMpower132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin+ pemetrexed in stage IV non-squamous NSCLCV Papadimitrakopoulou, M Cobo, R Bordoni, P Dubray-Longeras, ...Journal of Thoracic Oncology 13 (10), S332-S333, 20181692018
5-) IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD …D Spigel, F De Marinis, G Giaccone, N Reinmuth, A Vergnenegre, ...Annals of Oncology 30, v915, 20191642019